Clinical Trials

Find a Trial

Trial Summary

Protocol No.4T-14-1
StatusOPEN TO ACCRUAL
Principal InvestigatorCary, Clint
ScopeNational
PhasePhase II
Age GroupAdults and Children
TitlePhase II trial of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-2cm)
DescriptionThis phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Stage IIA pure seminoma OR stage I pure seminoma with isolated retroperitoneal relapse
  • Lymphadenopathy in the retroperitoneum: at least one lymph node 1-2 cm in greatest dimension, no lymph node > 2 cm in greatest dimension, no more than 2 lymph nodes 1-2 cm in greatest dimension
    • Axial imaging of lymphadenopathy within 6 weeks of the date of RPLND
    • Retroperitoneal lymphadenopathy must be within the RPLND template
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesTestis Cancer
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment